Treatment Options for Vitiligo: A review of Current and Future Therapies

November 18, 2026

The recent FDA approval of topical ruxolitinib represents the first therapy specifically indicated for vitiligo and marks a significant shift in the treatment paradigm for this historically underserved autoimmune condition. In parallel, several systemic therapies—including oral JAK inhibitors and novel biologic agents—are progressing through Phase 2 and Phase 3 clinical development. As the therapeutic landscape rapidly expands, dermatology clinicians must strengthen their understanding of vitiligo immunopathogenesis, key immune signaling pathways, and the mechanistic rationale linking targeted therapies to disease biology.
To address these educational needs, this initiative will consist of two live, CME-certified webinars and one podcast episode produced by the Science of Skin Summit. All content will be made available on-demand for 12 months following the live release, extending the educational reach and reinforcing sustained learning outcomes.

This webinar will offer a methodical overview of the phase 2-4 data for Ruxolitinib, and Phase 2 & 3 data
(if available) for povorcitinib, ritlecitinib and upadacitinib. Review mechanisms
of zasocitinib and brepocitinib. Review the efficacy of NBUVB and melanocyte
transfer.

Target Audience

This activity is designed for an audience of physicians, nurses, physician associates, Dermatologists, dermatology residents and fellows, dermatology-focused PAs and NPs.

Learning Objectives

• Interpret clinical trial data for ruxolitinib and emerging systemic therapies.

• Compare efficacy and durability outcomes across studies.

• Assess safety and monitoring considerations for JAK inhibitors and investigational agents.

• Individualize therapy based on disease characteristics and patient factors.

 

Commercial Support

This activity is supported from an independent medical education grant from Incyte Corporation.

 

Course summary

Available credit: 
  • 1.00 AAPA Category 1 CME

    Physician Associates
    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

  • 1.00 AMA PRA Category 1 Credit™

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC Contact Hours

    Nurses
    Credit being awarded: 1.00 ANCC contact hours

  • 1.00 AMA PRA Category 1 Credit™ Non-MD

    Non-Physicians Seeking AMA Credit
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™.

Course opens: 
10/27/2026
Course expires: 
12/18/2026
Event starts: 
11/18/2026 - 8:00pm EST
Event ends: 
11/18/2026 - 9:00pm EST
Cost:
$0.00
Add to calendar: 
Rating: 
0
Live Webinar
United States

All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product 
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer 
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.

Committee Member, Planner, Staff(s)

Dorothy Caputo, MA BSN RN

has no relevant financial relationships to disclose at this time.

Edward Lain, MD

has a financial relationship (Consultant) with Galderma;.
has a financial relationship (Advisor) with Galderma;.

Rebecca Lakofsky, BSN, RN

has no relevant financial relationships to disclose at this time.
Moderator(s)

Edward Lain, MD

has a financial relationship (Advisor) with Galderma;.
has a financial relationship (Consultant) with Galderma;.
Reviewer(s)

Dorothy Caputo, MA BSN RN

has no relevant financial relationships to disclose at this time.

Rebecca Lakofsky, BSN, RN

has no relevant financial relationships to disclose at this time.
Speaker, Instructor, Faculty(s)

Anisha Patel, MD

has a financial relationship (Consultant) with Erasca;.
has a financial relationship (Consultant) with FBIO Acquisition Corp LXI;.
has a financial relationship (Researcher) with Hoth Therapeutics;.
has a financial relationship (Consultant) with Ideology Health;.
has a financial relationship (Consultant) with Janssen Scientific Affairs, LLC;.
has a financial relationship (Consultant) with Lutris;.
has a financial relationship (Researcher) with Lutris;.
has a financial relationship (Advisor) with Revolution Medicines;.
has a financial relationship (Consultant) with Roche Pharma;.
has a financial relationship (Consultant) with SynOx Therapeutics;.
has a financial relationship (Royalties or patent beneficiary) with UpToDate, Inc;.
has a financial relationship (Advisor) with EMD Serono;.
has a financial relationship (Consultant) with Deciphera Pharmaceuticals, Inc.;.
has a financial relationship (Consultant) with Asymmetric Therapeutics, LLC;.
has a financial relationship (Consultant) with Astellas Pharma US, Inc;.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Science of Skin Summit, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Available Credit

  • 1.00 AAPA Category 1 CME

    Physician Associates
    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

  • 1.00 AMA PRA Category 1 Credit™

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC Contact Hours

    Nurses
    Credit being awarded: 1.00 ANCC contact hours

  • 1.00 AMA PRA Category 1 Credit™ Non-MD

    Non-Physicians Seeking AMA Credit
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™.

Price

Cost:
$0.00
Please login or register to take this course.

Criteria for Success
To obtain credit, you must participate in the entire activity.  Partial credit is not awarded.  Complete the post test and evaluation.   The Certificate of Completion is immediately available for download after submitting your evaluation.  It will remain in your profile transcript for future retrieval if needed.  It can be found under My Account > My Activities > Completed Activities.

If you have any questions, contact [email protected].